Medications

ASH: Daratumumab beneficial for patients with multiple myeloma

For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with ...

Oncology & Cancer

New insights into how the drug pomalidomide fights cancer

Multiple myeloma is a cancer of the white blood cells, and patients diagnosed with this disease commonly die within five years. Clinicians often treat multiple myeloma with the drug thalidomide and structurally similar drugs ...

Oncology & Cancer

Lenalidomide may delay onset of myeloma-related bone, organ damage

The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage. Results of the study, which ...

Medications

Daratumumab cuts risk for progression in multiple myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published ...

Oncology & Cancer

Rituximab plus lenalidomide effective in follicular lymphoma

(HealthDay)—Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England ...

page 1 from 4

Lenalidomide

Lenalidomide ( /lɛnəˈlɪdɵmaɪd/), initially known as CC-5013 and marketed as Revlimid by Celgene, is a derivative of thalidomide introduced in 2004.

It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Lenalidomide and bortezomib are considered therapeutic breakthroughs in the treatment of myeloma, which generally carries a poor prognosis.

This text uses material from Wikipedia, licensed under CC BY-SA